ライフサイエンスコーパス: UTI

1 UTIs are characterized by several chronic infections whi

2 We simulated a cohort that experienced 3 UTIs/year and a secondary cohort that experienced 8 UTIs

3 iew of management of women experiencing >/=3 UTIs per year.

4 ar and a secondary cohort that experienced 8 UTIs/year.

5 stionnaire and asked "Do you feel you have a UTI?" Women responding negatively were recruited into th

6 was attenuated in biofilm formation and in a UTI model.

7 est risk was seen among women who reported a UTI only (adjusted odds ratio = 2.3, 95% CI: 1.5, 3.5),

8 Infants born to women who reported a UTI were less likely than were others to have a very low

9 64%) of these 22 women were diagnosed with a UTI instead of an STI.

10 ring naturally occurring, community acquired UTI in women and multiple novel fitness genes used by UP

11 ns isolated from cases of community-acquired UTI, those isolated from cases of meningitis are more re

12 and the role of CD14 in host defense against UTI in the bladder.

13 ntation of the Cu-based host defense against UTI represents a novel approach to limiting bacterial co

14 l stealth siderophores and protected against UTI.

15 se to UTI and its role in protection against UTI remain unresolved.

16 derophore receptor proteins protects against UTI.

17 ies to develop innovative strategies against UTI caused by UPEC.

18 re selected as antigens to vaccinate against UTI for this vaccine strategy.

19 ncy because of its protective effect against UTIs.

20 between UMOD variants and protection against UTIs.

21 The pathogenesis of S. agalactiae UTI is complex, multifactorial, and influenced by virule

22 nd their female sex partners, 6 strains (all UTI causing) were shared between partners.

23 nfection (aOR, 2.09 [95% CI, 1.78-2.46]) and UTI (aOR, 1.93 [95% CI, 1.74-2.15]) and remained high in

24 iotic treatment strategy for elderly ASB and UTI patients is justified.

25 hereas that of intra-abdominal infection and UTI increased.

26 lluminates an interplay between host sex and UTI that is more complex than previously appreciated.

27 A mouse model of ascending UTI was utilized to determine the impact of coinfection

28 ngs to a murine model of catheter-associated UTI (CAUTI), delineated the contribution of enhanced ure

29 ith a chronic indwelling catheter-associated UTI and sepsis hospitalized in medical departments.

30 Quality, aimed to reduce catheter-associated UTI in intensive care units (ICUs) and non-ICUs.

31 The unadjusted catheter-associated UTI rate decreased overall from 2.82 to 2.19 infections

32 theter use (P=0.004) and catheter-associated UTI rates (P=0.001).

33 90 to 0.96; P<0.001) and catheter-associated UTI rates decreased from 2.28 to 1.54 infections per 100

34 In an adjusted analysis, catheter-associated UTI rates decreased from 2.40 to 2.05 infections per 100

35 reduce catheter use and catheter-associated UTI rates in non-ICUs.

36 Data on catheter use and catheter-associated UTI rates were collected during three phases: baseline (

37 Catheter use and catheter-associated UTI rates were largely unchanged in ICUs.

38 nges in catheter use and catheter-associated UTI rates.

39 icated and complicated), catheter-associated UTI, and asymptomatic bacteriuria in both women and men.

40 important in preventing catheter-associated UTI.

41 ors in the prevention of catheter-associated UTI.

42 eline resistance of BALB/c mice to bacterial UTI despite prior exposure to S. haematobium eggs.

43 of antibiotic therapy for ASB, cystitis, CA-UTI and pyelonephritis were 10.0 (4.5), 11.4 (4.7), 12.0

44 has potential for use in rapid point-of-care UTI screening.

45 ethra to the urinary tract, where they cause UTIs.

46 An ESBL-producing ST131-H30Rx strain caused UTI in 2 siblings, plus asymptomatic intestinal coloniza

47 fficacy in mouse models of acute and chronic UTI.

48 rthermore, in mice with a history of chronic UTI, cyclooxygenase-2-dependent inflammation allowed a v

49 ce has complicated the management of chronic UTIs and necessitates new preventative strategies.

50 Clinical UTI with pyuria was also significantly reduced (incidenc

51 xpression of Cu efflux genes during clinical UTI in patients as an adaptive response to host-derived

52 urinary Cu content observed during clinical UTI.

53 uice beverage lowered the number of clinical UTI episodes in women with a recent history of UTI.

54 was defined as the total number of clinical UTI events (including multiple events per subject when a

55 investigator-diagnosed episodes of clinical UTI in the cranberry group compared with 67 episodes in

56 One clinical UTI event was prevented for every 3.2 woman-years (95% C

57 The primary outcome was the clinical UTI incidence density, which was defined as the total nu

58 a cranberry beverage on episodes of clinical UTIs.

59 I-positive E. coli in uncomplicated clinical UTIs.

60 re professionals correctly diagnosed E. coli UTI and negative urine cultures, which would help preven

61 e hundred thirty-three children with E. coli UTI who attended a reference children's hospital between

62 w that, in mice, an initial Escherichia coli UTI, whether chronic or self-limiting, leaves a long-las

63 human cohort of women with recurrent E. coli UTIs, urine LCN2 levels were associated with UTI episode

64 high for most cases of MDR Escherichia coli UTIs.

65 ntibiotic use in patients with a complicated UTI seems to reduce length of hospital stay and therefor

66 tibiotic use for patients with a complicated UTI, as defined by these QIs, and length of hospital sta

67 dy included 1252 patients with a complicated UTI, hospitalized at internal medicine and urology depar

68 opulations; indeed, morbidity in complicated UTI is higher in males.

69 sons at risk of recurrent and/or complicated UTI.

70 idney transplant recipients with complicated UTIs underwent both PET with a specific CXCR4 ligand, (6

71 py numbers in 298 individuals with confirmed UTIs and vesicoureteral reflux from the Randomized Inter

72 To date, UTIs are mainly treated with antibiotics, leading to the

73 ch to limiting bacterial colonization during UTI.

74 as the molecular source of urinary Cu during UTI.

75 inary copper (Cu) content is elevated during UTI caused by uropathogenic Escherichia coli (UPEC).

76 PEC are involved in promoting fitness during UTI in humans.

77 reveal that Cu is mobilized to urine during UTI caused by the major uropathogens Proteus mirabilis a

78 is a host effector mobilized to urine during UTI to limit bacterial growth.

79 ion of mrpJ mimicking levels observed during UTIs leads to differential expression of 217 genes relat

80 e pointed to the need for safe and effective UTI-prevention strategies such as cranberry consumption.

81 ould be developed to better inform empirical UTI therapy selection in the ED.

82 osttransplant diarrhea, AR, and Enterococcus UTI.

83 95%) in the three patients with Enterococcus UTI compared to 0% in the 23 patients without Enterococc

84 o 0% in the 23 patients without Enterococcus UTI (interquartile range, 0.00%-0.08%) (P=0.005, Wilcoxo

85 ) was designed and fabricated for evaluating UTI (E. coli) and STD (Neisseria gonorrhoeae) from human

86 Experimental UTI was induced in wild-type (WT) and hepcidin-knockout

87 Experimental UTI with UPEC in nonhuman primates recapitulates the inc

88 sex, age, (urological) comorbidity, febrile UTI, and intensive care unit admission <24 hours.

89 Delay in treatment of febrile UTIs and permanent renal scarring are associated.

90 However, significantly fewer UTIs caused by E coli of any serotype were noted in the

91 opments in the quest for new diagnostics for UTI and the need for more sophisticated techniques in te

92 cal diagnostic criterion (>10(5) CFU/mL) for UTI.

93 en under 25 years of age, the odds ratio for UTI only was 2.6 (95% CI: 1.7, 4.0), and among older wom

94 Testing for UTI is easily performed in the clinic using dipstick tes

95 ren, clinicians should not delay testing for UTI.

96 In this population, empirical therapy for UTI without urine culture testing and overdiagnosis of U

97 trongly discouraged as first-line agents for UTIs.

98 f community-based antibiotics prescribed for UTIs (1.31; 95% CI, 1.29 to 1.33), Staphylococcus aureus

99 meningitis and less than 1% of isolates from UTI were resistant to third-generation cephalosporins.

100 in urogenital anatomy confer protection from UTI in males; however, as clinically observed, male sex

101 Future UTI-preventive probiotic strains may benefit by retainin

102 Outcomes studied included reflux grade, UTIs during the study on placebo or antibiotics, bowel a

103 anisms involved in pathogenesis during human UTIs.

104 gA, and capsule to study the role of CovR in UTI.

105 lactiae global virulence regulator, CovR, in UTI pathogenesis is unknown.

106 l model for interrogating sex differences in UTI susceptibility and pathogenesis, and illuminates an

107 The repertoire of UPEC genes involved in UTI presented here will facilitate further translational

108 ng ferroxidase, is found at higher levels in UTI urine than in healthy control urine and serves as th

109 ation of antimicrobial therapy for the index UTI.

110 Urinary tract infection (UTI) (28.5%), and spontaneous bacterial peritonitis (SBP

111 ng clinical E. coli urinary tract infection (UTI) and experimental human colonization with a commensa

112 set or prognosis of urinary tract infection (UTI) and some sexually-transmitted diseases (STDs), such

113 lled by CD14 during urinary tract infection (UTI) are unknown.

114 young children had urinary tract infection (UTI) caused by an extended-spectrum beta-lactamase (ESBL

115 th an ICD 9/10 code urinary tract infection (UTI) diagnosis during July 2015 to June 2016 were random

116 Catheter-associated urinary tract infection (UTI) is a common device-associated infection in hospital

117 Urinary tract infection (UTI) is a major global infectious disease affecting mill

118 cteriuria (ASB) and urinary tract infection (UTI) is based on the presence of diverse symptoms, inclu

119 Urinary tract infection (UTI) is one of the most common infections in children.

120 enetic variation to urinary tract infection (UTI) risk in children with vesicoureteral reflux is larg

121 istory of recurrent urinary tract infection (UTI) to receive a single injection of either intramuscul

122 For urinary tract infection (UTI), a history of two or more episodes is an independen

123 es were symptomatic urinary tract infection (UTI), all-cause death, all-cause hospitalization, all mu

124 oli (UPEC)-mediated urinary tract infection (UTI), its contribution to UPEC pathogenesis is unknown.

125 nt of uncomplicated urinary tract infection (UTI), manifested by inflammation of the urinary bladder,

126 with a complicated urinary tract infection (UTI), we developed in a previous study a key set of 4 va

127 nd risk factors for urinary tract infection (UTI), were recorded.

128 dressed its role in urinary tract infection (UTI), which remains largely unknown.

129 women experiencing urinary tract infection (UTI)-like symptoms.

130 minal infection, or urinary tract infection (UTI).

131 galactiae can cause urinary tract infection (UTI).

132 erity in a model of urinary tract infection (UTI).

133 nd protects against urinary tract infection (UTI).

134 d with Enterococcus urinary tract infection (UTI).

135 ost common agent of urinary tract infection (UTI).

136 model of bacterial urinary tract infection (UTI).

137 not been studied in urinary tract infection (UTI).

138 ins associated with urinary tract infection (UTI).

139 Urinary tract infections (UTI) are one of the most common bacterial infections and

140 use of 150 million Urinary Tract Infections (UTI) reported annually world-wide.

141 community-acquired urinary tract infections (UTI) that occurred during the same time period and in th

142 s for 80 to 90% of urinary tract infections (UTI), and the increasing rate of antibiotic resistance a

143 t of uncomplicated urinary tract infections (UTI).

144 about urine, bladder, or kidney infections (UTIs) and cervical or vaginal infections (CVIs) during p

145 ical isolates from urinary tract infections (UTIs) after 15 min of exposure for all four antibiotic c

146 Urinary tract infections (UTIs) and sexually transmitted infections (STIs) are com

147 0 men with febrile urinary tract infections (UTIs) and their female sex partners, 6 strains (all UTI

148 Urinary tract infections (UTIs) are a common occurrence in children.

149 Recurrent urinary tract infections (UTIs) are a common problem among women.

150 Urinary tract infections (UTIs) are a major burden to human health.

151 Urinary tract infections (UTIs) are a microbial disease reported worldwide.

152 Urinary tract infections (UTIs) are among the most common bacterial infections and

153 Urinary tract infections (UTIs) are among the most common bacterial infections, ca

154 Urinary tract infections (UTIs) are among the most commonly treated bacterial infe

155 Urinary tract infections (UTIs) are common health-care-associated infections.

156 Urinary tract infections (UTIs) are common in both inpatient and outpatient settin

157 Urinary tract infections (UTIs) are frequent and lead to a large number of clinica

158 Complicated urinary tract infections (UTIs) are frequent in immunosuppressed patients after ki

159 Urinary tract infections (UTIs) are frequently encountered in clinical practice an

160 Urinary tract infections (UTIs) are one of the most common bacterial infections in

161 Urinary tract infections (UTIs) are potentially life threatening infections that a

162 Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) af

163 ultidrug-resistant urinary tract infections (UTIs) disrupt the gut microbiome and promote antibiotic

164 Urinary tract infections (UTIs) occur predominantly in females but also affect sub

165 fragmentation, and urinary tract infections (UTIs) within 3 mo of transplantation.

166 ections, including urinary tract infections (UTIs), bacteremia, and infective endocarditis.

167 e vast majority of urinary tract infections (UTIs), is a leading cause of adult bacteremia, and is th

168 Urinary tract infections (UTIs), predominantly caused by uropathogenic Escherichia

169 or the majority of urinary tract infections (UTIs), which are some of the world's most common bacteri

170 py for symptomatic urinary tract infections (UTIs), yet large-scale evaluations of bacteriuria manage

171 e of uncomplicated urinary tract infections (UTIs).

172 tibiotic-resistant urinary tract infections (UTIs).

173 sative pathogen of urinary tract infections (UTIs).

174 atheter-associated urinary tract infections (UTIs).

175 e primary cause of urinary tract infections (UTIs).

176 d particularly for urinary tract infections (UTIs, 1.41; 95% CI, 1.35 to 1.45), skin infections (1.50

177 c parental strain, TX82, in a mixed-inoculum UTI model (P < 0.001 to 0.048), that reconstitution of e

178 que that yields reproducible upper and lower UTI in both male and female mice, enabling studies of se

179 allograft infection in 9 patients and lower UTI/nonurologic infections in the remaining 4 patients.

180 gnostic marker to distinguish APN from lower UTI and function as a diagnostic marker indicative of VU

181 ESR and DNI were higher in APN than in lower UTI (p < 0.01).

182 e recently to carbapenems and colistin, make UTI a prime example of the antibiotic-resistance crisis

183 physiological changes, like frequency, mimic UTI symptoms, and therefore bacteriological cultures are

184 Modelling UTIs in vitro, human vaginal and bladder epithelial cell

185 e, sensitive urinalysis biosensor to monitor UTI and gonorrhea from human urine.

186 eases an individual's susceptibility to MRSA UTI.

187 ional antigens suitable for a multicomponent UTI vaccine and highlights the potential use of bacteria

188 nce to urothelial cells in vitro In a murine UTI model, the DeltarfaG mutant had the most severe defe

189 Currently, no UTI vaccines are approved for use in the United States,

190 onding negatively were recruited into the no-UTI cohort, while women responding affirmatively were re

191 unosensor was tested using other UTI and non-UTI bacteria, Staphylococcus, Klebsiella, Proteus and Sh

192 After excluding patients with non-UTI indications for antibiotics, 72% of patients with AS

193 sk sample, maternal gestational CVI, but not UTI, was associated with a higher risk of impaired motor

194 and comparative transcriptional analysis of UTI samples to the UPEC isolates cultured in human urine

195 This review brings all the major concerns of UTI at one's doorstep such as clinical costs and inciden

196 ermine the accuracy of clinical diagnoses of UTI and STI in adult women presenting with genitourinary

197 mong women who were not given a diagnosis of UTI, or reflect preconditioning.

198 thogens and pyuria confirms the diagnosis of UTI.

199 The apparent protective effect of UTI might be spurious, reflect confounding due to untrea

200 I episodes in women with a recent history of UTI.

201 However, mechanistic knowledge of UTI pathogenesis has come almost exclusively from studie

202 plied, 10j was effective in a mouse model of UTI by reducing the bacterial load in the bladder by abo

203 ere generated using an experimental model of UTI.

204 technical obstacles, preclinical modeling of UTI in male mice has been limited.

205 d human bladder uroepithelial cell models of UTI and S. agalactiae mutants in covR and related factor

206 monstrated oral activity in animal models of UTI but were found to have limited compound exposure due

207 en primarily examined using murine models of UTI.

208 t urine culture testing and overdiagnosis of UTI were common and associated with unnecessary antibiot

209 When there is a low pretest probability of UTI, a negative dipstick result for leukocyte esterase a

210 mproved antibiotic susceptibility profile of UTI-causing organisms.

211 be important in the onset and progression of UTI.

212 i (UPEC), the most common causative agent of UTIs, invades bladder epithelial cells (BECs) and develo

213 In post-hoc exploratory analyses of UTIs with higher bacterial counts (>/=10(5) colony-formi

214 When we considered the joint association of UTIs and young maternal age, a synergistic effect was ob

215 majority of stent complications consisted of UTIs, with an incidence of 31 of 126 (24.6%) in the late

216 as an aid in the point-of-care diagnosis of UTIs especially in emergency and primary care settings.

217 antibody functionality, and the incidence of UTIs caused by E coli vaccine serotypes in each group.

218 No reduction in the incidence of UTIs with 10(3) or more colony-forming units per mL of v

219 The overwhelming majority of UTIs are caused by uropathogenic Escherichia coli (UPEC)

220 linically relevant overview of management of UTIs, including screening, diagnosis, treatment, and pre

221 urinary levels of uromodulin and markers of UTIs in the general population substantiates the link be

222 mannosides could markedly reduce the rate of UTIs and recurrent UTIs.

223 rval [CI], 1.14-4.33) and 56% higher risk of UTIs or pyelonephritis (aHR, 1.56; 95% CI, 1.05-2.30) in

224 ation was associated only with early risk of UTIs or pyelonephritis.

225 The clinical spectrum of UTIs ranges from asymptomatic bacteriuria, to symptomati

226 of this immunosensor was tested using other UTI and non-UTI bacteria, Staphylococcus, Klebsiella, Pr

227 uide optimal empiric treatment of outpatient UTIs.

228 ommon factor in the management of outpatient UTIs.

229 Bacteriuria commonly precedes UTI and is often treated with antibiotics, particularly

230 reinforces the need for vaccines to prevent UTIs and recurrent infections.

231 coded by DEFA1A3, is important in preventing UTIs but has not been investigated in the vesicoureteral

232 The prevalence of culture-proven UTI among pregnant women with UTI symptoms was 4%.

233 ty-seven (12%) patients had a culture-proven UTI.

234 ical trial, women with a history of a recent UTI were assigned to consume one 240-mL serving of cranb

235 difficile, significantly decreased recurrent UTI frequency, and improved antibiotic susceptibility pr

236 is the most effective strategy for recurrent UTI prevention compared to daily cranberry pills, daily

237 he development of therapeutics for recurrent UTI.

238 Markov chain Monte Carlo model of recurrent UTI for each management strategy with >/=2 adequate tria

239 ional copy of DEFA1A3, the odds of recurrent UTI in patients receiving antibiotic prophylaxis decreas

240 ber did not associate with risk of recurrent UTI.

241 zation resistance and cause severe recurrent UTI, which could be prevented by cyclooxygenase-2 inhibi

242 nce of IBC/IIB was associated with recurrent UTI (odds ratio [OR], 3.3; 95% confidence interval [CI],

243 a high proportion of children with recurrent UTI.

244 ic bacteriuria, to symptomatic and recurrent UTIs, to sepsis associated with UTI requiring hospitaliz

245 rkedly reduce the rate of UTIs and recurrent UTIs.

246 ed cases, 1 in 40 women experience recurrent UTIs.

247 apy, 30-50% of patients experience recurrent UTIs.

248 ectiveness strategies for managing recurrent UTIs are lacking.

249 EFA1A3 copy number associated with recurrent UTIs in subjects in the RIVUR Study randomized to prophy

250 uld be considered in patients with recurrent UTIs.

251 ying the epidemiological evidence of reduced UTI incidence in breast-fed infants.

252 younger than 6 years with a first or second UTI were followed up for 2 years.

253 nits per mL), the number of vaccine serotype UTIs did not differ significantly between groups (0.046

254 served, male sex associated with more severe UTI once these traditional anatomic barriers were bypass

255 isms, antibiotics administered for suspected UTI, and total antimicrobial administration.

256 viewed 312 pediatric patients with suspected UTI who had urine culture, UA, and urine Gram stain perf

257 .46), antibiotics administered for suspected UTIs (692 vs 909 antibiotic days; 8.3 vs 10.8 antibiotic

258 Symptomatic UTI developed in 4 of 24 patients (16.7%; 95% CI, 6.1%-3

259 associated with higher risk for symptomatic UTI.

260 clinical diagnostic criteria for symptomatic UTI: fever, worsened urinary urgency or frequency, acute

261 ia should be differentiated from symptomatic UTI.

262 te asymptomatic bacteriuria from symptomatic UTI.

263 Establishing a diagnosis of symptomatic UTI in older women requires careful clinical evaluation

264 The diagnosis of symptomatic UTI is made when a patient has both clinical features an

265 or 1 year for the development of symptomatic UTI.

266 Risk factors for recurrent symptomatic UTI include diabetes, functional disability, recent sexu

267 rogen therapy effectively reduce symptomatic UTI episodes and should be considered in patients with r

268 durations of therapy for ASB and symptomatic UTIs.

269 ificant differences in number of symptomatic UTIs (10 episodes in the treatment group vs 12 in the co

270 ults of this study add further evidence that UTIs may increase the risk of gastroschisis.

271 This indicates that UTIs are sometimes sexually transmitted.

272 of inflammation and pain, were found in the UTI and ASB cohorts.

273 nstitution of empA restored virulence in the UTI model, and that deletion of empA also resulted in at

274 In the UTI model, mice coinfected with the two species exhibite

275 onding affirmatively were recruited into the UTI cohort; the latter cohort was reassessed with the UT

276 immune responses in cases of ASB compared to UTI in elderly patients who were hospitalized upon injur

277 is mobilized to urine as a host response to UTI and its role in protection against UTI remain unreso

278 der, ureters, and kidneys of mice subject to UTI.

279 rone, suggesting that male susceptibility to UTI is strongly influenced by androgen exposure.

280 The time to UTI with culture positivity did not differ significantly

281 for all four antibiotic classes relevant to UTIs.

282 UPEC isolates, while simultaneously treating UTI, without notably disrupting the structural configura

283 sed by bacteria during natural uncomplicated UTI.

284 ng roles for CD14 in the bladder during UPEC UTI.

285 aracterized using a self-completed validated UTI symptom assessment (UTISA) questionnaire and asked "

286 s in an antimicrobial peptide associate with UTI risk.

287 Pyuria is associated with UTI and implicates host immune responses via release of

288 UTIs, urine LCN2 levels were associated with UTI episodes and with levels of bacteriuria.

289 nd recurrent UTIs, to sepsis associated with UTI requiring hospitalization.

290 intracellular bacteria (IB) in children with UTI caused by E. coli and to characterize its virulence

291 rom those seen in most elderly patients with UTI and warrant larger clinical studies to assess whethe

292 ts diagnosed with ASB compared to those with UTI.

293 culture-proven UTI among pregnant women with UTI symptoms was 4%.

294 studied, providers diagnosed 175 (66%) with UTIs, 100 (57%) of whom were treated without performing

295 riuria among pregnant women with and without UTI symptoms in Uganda.

296 YbcL(UTI) was released to a greater extent during UPEC infect

297 As YbcL(UTI) acts on the uroepithelium to attenuate neutrophil m

298 Instead, YbcL(UTI) was liberated during bacterial death, which was aug

299 the presence of a uroepithelial layer; YbcL(UTI) did not inhibit neutrophil chemotaxis directly.

300 ion of neutrophil migration by purified YbcL(UTI), encoded by cystitis isolate UTI89, required the pr